NCT04091295 2026-03-04BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastAveni FoundationAvailable
NCT04566393 2026-01-28Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesxCuresAvailable
NCT06132191 2025-11-20Expanded Access Use of Cemiplimab in Patients With Solid TumorsRegeneron PharmaceuticalsApproved for marketing
NCT06099639 2025-06-08Medical Access Program for Patritumab DeruxtecanDaiichi SankyoNo longer available
NCT04100694 2025-05-20Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorMerus B.V.Approved for marketing